A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions

European Respiratory Journal

Volumn 41, Issue 1, 2013, Pages 18-24

  Hooper, Clare E ^a   Morley, Anna J ^a   Virgo, Paul ^a   Harvey, John E ^a   Kahan, Brennan ^b   Maskell, Nick A ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Benign asbestos related effusion; Biomarker; Diagnosis; Malignancy; Mesothelioma; Predictive value

Indexed keywords

MESOTHELIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INTERMETHOD COMPARISON; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PLEURA FLUID; PLEURA MESOTHELIOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BODY FLUIDS; FEMALE; GPI-LINKED PROTEINS; HUMANS; MALE; MIDDLE AGED; PLEURAL EFFUSION; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84872193691     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00148211     Document Type: Article

References (24)

1. Musk AW, De Klerk N. Epidemiology of malignant mesothelioma in Australia. Lung Cancer 2004; 45: S21-S23.
2. Light RW, Lee YCG, eds. Textbook of Pleural Diseases. 2nd Edn. London, Hodder Arnold, 2008.
3. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007; 62: Suppl. 2, ii1-ii19.
4. Kutty CPK, Remeniuk E, Varkey B. Malignant-appearing cells in pleural effusions due to pancreatitis. Acta Cytol 1981; 25: 412-416.
5. Traill ZC, Davies RJO, Gleeson FV. Thoracic computed tomography in patients with suspected malignant effusions. Clin Radiol 2001; 56: 193-196.
6. Hooper CE, Lee YCG, Maskell NA. Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010. Thorax 2010; 65: Suppl. 2, ii4-ii17.
7. Luo L, Shi H-Z, Liang Q-L, et al. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Respir Med 2010; 104: 149-156.
8. Creaney J, Yeoman D, Naumoff LK, et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007; 62: 569-576.
9. Davies HE, Sadler RS, Bielsa S, et al. Clinical Impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med 2009; 180: 437-444.
10. Boudville N, Paul R, Robinson BWS, et al. Mesothelin and kidney function - analysis of relationship and implications for mesothelioma screening. Lung Cancer 2011; 73: 320-324.
11. Hollevoet K, Bernard D, De Geeter F, et al. Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum. Clin Chem 2009; 55: 1431-1433.
12. Hollevoet K,Nackaerts K, Thas O, et al. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Chest 2012; 141: 477-484.
13. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173: 1155-1160.
14. Creaney J, Van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007; 132: 1239-1246.
15. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007; 13: 5076-5081.
16. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-1616.
17. Creaney J, Christansen H, Lake R, et al. Soluble mesothelin related protein in mesothelioma. J Thorac Oncol 2006; 1: 172-174.
18. Chang K, Pastan I, Willingham MC. Isolation and characterisation of monoclonal antibody K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992; 50: 373-381.
19. Creaney J, Robinson BW. Detection of malignant mesothelioma in asbestos exposed individuals: the potential role of soluble mesothelin-related protein. Haematol Oncol Clin North Am 2005; 19: 1025-1040.
20. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003; 16: 192-197.
21. Creaney J, Francis RJ, Dick IM, et al. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumour volume, clinical stage and changes in tumour burden. Clin Cancer Res 2011; 17: 1181-1189.
22. Grigoriu BD, Chahine B, Vachani A, et al. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med 2008; 179: 950-954.
23. Wheatley-Price P, Yang B, Patsios D, et al. Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010; 28: 3316-3322.
24. Hollevoet K, Nackaerts K, Gosselin R, et al. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Clin Oncol 2011; 6: 1930-1937.